Definition: Obesity is a common, chronic disease marked by an unhealthy amount of body fat, as the NCI dictionary puts it. In practice it is defined by body mass index (BMI), weight in kilograms divided by height in meters squared. NIDDK lists a BMI of 30 or more in adults as obesity, 25 to 29.9 as overweight, and 40 or more as severe obesity.
Worked example
NIDDK cites survey data from 2017 to 2018 showing 42.4% of US adults have obesity and 9.2% severe obesity. The NCI lists heart disease, stroke, high blood pressure, diabetes, sleep apnea, arthritis, kidney disease and some cancers among the problems it can lead to.
Wegovy, Zepbound and Saxenda are approved, with a reduced-calorie diet and more activity, for adults with obesity, or with overweight plus at least one weight-related condition. Wegovy is also approved to lower the risk of major heart events in adults with heart disease and obesity or overweight, and Zepbound to treat moderate to severe obstructive sleep apnea in adults with obesity.
Weekly weigh-ins next to dose dates and titration steps show how weight moved at each dose, which is what a prescriber looks at before the next step.
Read more on Dose Track: Weight loss · Wegovy side effects · Zepbound side effects · Wegovy vs Zepbound